Ritter Pharmaceuticals (NASDAQ:RTTR) Trading 11.1% Higher

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) shares traded up 11.1% during mid-day trading on Thursday . The stock traded as high as $0.30 and last traded at $0.30, 1,725,469 shares were traded during mid-day trading. An increase of 270% from the average session volume of 466,688 shares. The stock had previously closed at $0.27.

Several analysts have issued reports on the company. ValuEngine lowered Ritter Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Zacks Investment Research lowered Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th.

The company has a market capitalization of $3.01 million, a P/E ratio of -0.08 and a beta of 1.24. The business has a 50 day moving average of $0.94 and a 200-day moving average of $0.92.

Ritter Pharmaceuticals (NASDAQ:RTTR) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.18.

Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Further Reading: How interest rates affect municipal bond prices

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.